Navigation Links
Hybrid antibodies to protect from small pox infection

Researchers Robert H. Purcell, NIAID's Laboratory of Infectious Diseases, and Bernard Moss, NIAID's Laboratory of Viral Diseases have developed a hybrid antibody// which is found to prevent and treat small pox virus infection. Though Small pox virus as been eradicated world wide, there is an increased fear over the use of small pox virus as a bioterrorism tool to kill people.

Small pox referral strains are only available in two places in the world one at CDC, Atlanta and the other at Russian Laboratory. Anti-vaccinia immune globulin (VIG) is the vaccine used worldwide against small pox virus which is prepared from producing antibodies against a weak attenuated smallpox strain in humans and collecting these humanized antibodies from volunteers which can offer immunity against small pox wild strain. The newly prepared vaccine is a hybrid antibody from both chimpanzees and humans immunized antibody, this hybrid antibody as been found to be very effective in controlling the virus in small pox infected mice. The researchers have reported the results of their study in Proceedings of the National Academy of Sciences (PNAS).

Researchers feel that the new hybrid vaccine would be better than the VIG vaccine which causes serious complications in immunocompromised and children’s with skin diseases. The Hybrid vaccine was prepared from combining the antibodies derived from humans and chimpanzees, the bone marrow of hyper-immunized chimpanzees that effectively neutralizes the B5 protein of the virus and also contains the antibodies isolated from small pox humanized individuals containing the two antibodies 8AH7AL and 8AH8AL which effectively neutralized the virus.
'"/>




Page: 1

Related medicine news :

1. NHS To Be Reformed By Using A Hybrid Approach
2. Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced
3. Hybrid Nanoparticles for Multimodal Medical Imaging
4. Hybrid Molecule Causes Cancer Cells to Self-Destruct
5. Mutating viruses helps produce antibodies
6. Monoclonal antibodies show promise in treatment of blood cancer
7. Transdermal HRT not cardioprotective in postmenopausal women with CAD
8. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
9. Antioxidants protect health tissue in people undergoing radiation therapy.
10. Morning after pill effective up to five days after having unprotected sex
11. Cats to protect children from asthma
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: